{"id":611795,"date":"2022-08-12T18:54:01","date_gmt":"2022-08-12T18:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=611795"},"modified":"2022-08-12T18:54:01","modified_gmt":"2022-08-12T18:54:01","slug":"mesothelioma-market-to-observe-stupendous-growth-during-the-forecast-period-delveinsight-key-companies-amphera-pharmamar-morphosys-bayer-targovax-pfizer-merck-trizell-astrazeneca-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/mesothelioma-market-to-observe-stupendous-growth-during-the-forecast-period-delveinsight-key-companies-amphera-pharmamar-morphosys-bayer-targovax-pfizer-merck-trizell-astrazeneca-others_611795.html","title":{"rendered":"Mesothelioma Market to Observe Stupendous Growth During the Forecast Period &#8211; DelveInsight | Key Companies &#8211; Amphera, PharmaMar, MorphoSys, Bayer, Targovax, Pfizer, Merck, Trizell, AstraZeneca, Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Mesothelioma Market to Observe Stupendous Growth During the Forecast Period - DelveInsight | Key Companies - Amphera, PharmaMar, MorphoSys, Bayer, Targovax, Pfizer, Merck, Trizell, AstraZeneca, Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Mesothelioma Market to Observe Stupendous Growth During the Forecast Period - DelveInsight | Key Companies - Amphera, PharmaMar, MorphoSys, Bayer, Targovax, Pfizer, Merck, Trizell, AstraZeneca, Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight, the Mesothelioma market size is expected to increase during the forecast period (2022-2032). Among the 7MM countries, the United States is expected to hold the major chunk of the market share. Promising treatments like immunotherapy, gene therapy, and photodynamic therapy have shown early success in extending life expectancy in various clinical trials and can create a significant impact on the mesothelioma market in the near future.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;<strong>Mesothelioma Market Insights, Epidemiology, and Market Forecast 2032&#8243;<\/strong> report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Mesothelioma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Mesothelioma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/9da8482369c949248a41672bc8d79d43.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mesothelioma: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Mesothelioma is a rare, aggressive form of malignant tumor that is caused by inhaled asbestos fibers and forms in the lining of the lungs, abdomen, or heart. There are four primary types of mesothelioma based on tumor location <strong>Pleural Mesothelioma (MPM), Peritoneal Mesothelioma, Pericardial Mesothelioma, and Testicular Mesothelioma<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><em>Pleural mesothelioma is a cancer of the pleura, which is the mesothelium surrounding the lungs, and it is the most common type of mesothelioma, accounting for 80 &ndash; 90% of all diagnosed cases. Because males are exposed to asbestos more often, they are more likely to be diagnosed with mesothelioma.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mesothelioma Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>The total incident cases of Mesothelioma in the 7MM were observed to be <strong>13,028 cases<\/strong> in 2017, which are estimated to decline during the study period.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>Mesothelioma incidence rates in most of the 7MM countries (except <strong>Spain<\/strong> and <strong>Japan<\/strong>) are declining due to reduced population-wide exposure to asbestos. Among the European Countries, the highest Mesothelioma incident cases were observed in the <strong>UK<\/strong> in 2017.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>In EU-5 countries, the highest number of incident cases of Mesothelioma was found in the<strong> United Kingdom<\/strong>, with <strong>2,804 cases<\/strong> in 2017, followed by <strong>Germany<\/strong> and <strong>Italy<\/strong>. Spain accounted for the least number of incident cases in 2017.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>As per Delveinsight, the<strong> United States<\/strong> accounted for nearly <strong>3,200 mesothelioma cases<\/strong> for the year 2017.<\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/mesothelioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Mesothelioma Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Mesothelioma market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report details the <strong>Mesothelioma market trend<\/strong> for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mesothelioma Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mesothelioma Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Mesothelioma market<\/strong> or expected to get launched during the study period. The analysis covers Mesothelioma market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Mesothelioma Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mesothelioma Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">Currently, there is no cure for mesothelioma, and approximately <strong>40%<\/strong> of mesothelioma patients survive at least one year. However, combining several treatments (i.e., multimodal approach) such as surgery, chemotherapy, and radiation therapy has helped some people live longer.<\/p>\n<p style=\"text-align: justify;\"><em>Over the last few years, pemetrexed was the only treatment available, but&nbsp;<strong>Optune Lua plus chemotherap<\/strong>y has got US FDA approval in the first line and Opdivo approval in relapsed or refractory settings in <strong>Japan&nbsp;<\/strong>has provided some treatment options for mesothelioma patients.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>As per DelveInsight, the Mesothelioma market dynamics are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in R&amp;D activities.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key Companies in the Mesothelioma Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck Sharp &amp; Dohme Corp.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Trizell<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amphera BV<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polaris Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Hoffmann-La Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sellas Life Sciences Group<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Momotaro-Gene<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PharmaMar<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Boehringer Ingelheim Limited<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck KGaA<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sumitomo Dainippon Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bayer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ImmunoGen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MorphoSys<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Targovax<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kissei Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TCR2 Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Atara Biotherapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bellicum Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Takeda (Millennium Pharmaceuticals)<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Mesothelioma Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">TR002<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TC-210<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ONCOS-102<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Alisertib (MLN8237)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Imfinzi<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Anetumab Ravtansine (BAY 94-9343)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tecentriq Plus Avastin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MesoPher<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pegargiminase<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">YS110<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">iCasp9M28z<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Napabucasin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Galinpepimut-S (Vaccine)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lurbinectedin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MTG201 Plus Nivolumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Yondelis (trabectedin)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nintedanib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Avelumab<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Mesothelioma Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Mesothelioma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Mesothelioma Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Mesothelioma Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Mesothelioma Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Mesothelioma Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Mesothelioma Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Mesothelioma Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Mesothelioma Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Mesothelioma Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Mesothelioma Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Mesothelioma Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Mesothelioma Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Mesothelioma Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Mesothelioma Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Mesothelioma Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Report by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/shoulder-replacement-devices-market\">Shoulder Replacement Devices Market<br \/><\/a><\/strong>&ldquo;Shoulder Replacement Devices Market&rdquo; research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Shoulder Replacement Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Shoulder Replacement Devices market.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=mesothelioma-market-to-observe-stupendous-growth-during-the-forecast-period-delveinsight-key-companies-amphera-pharmamar-morphosys-bayer-targovax-pfizer-merck-trizell-astrazeneca-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=mesothelioma-market-to-observe-stupendous-growth-during-the-forecast-period-delveinsight-key-companies-amphera-pharmamar-morphosys-bayer-targovax-pfizer-merck-trizell-astrazeneca-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight, the Mesothelioma market size is expected to increase during the forecast period (2022-2032). Among the 7MM countries, the United States is expected to hold the major chunk of the market share. Promising treatments &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/mesothelioma-market-to-observe-stupendous-growth-during-the-forecast-period-delveinsight-key-companies-amphera-pharmamar-morphosys-bayer-targovax-pfizer-merck-trizell-astrazeneca-others_611795.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[426,405,417,406,404],"tags":[],"class_list":["post-611795","post","type-post","status-publish","format-standard","hentry","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/611795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=611795"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/611795\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=611795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=611795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=611795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}